Identification

Name
Tropicamide
Accession Number
DB00809  (APRD00287)
Type
Small Molecule
Groups
Approved
Description

One of the muscarinic antagonists with pharmacologic action similar to atropine and used mainly as an ophthalmic parasympatholytic or mydriatic. [PubChem]

Structure
Thumb
Synonyms
  • Tropicamid
  • Tropicamida
  • Tropicamide
  • Tropicamidum
External IDs
Ro 1-7683
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Minims Tropicamide 1%Solution / drops1 %OphthalmicValeant Canada Lp Valeant Canada S.E.C.1995-12-31Not applicableCanada
MydriacylSolution0.5 %OphthalmicNovartis1951-12-31Not applicableCanada
MydriacylSolution1 %OphthalmicNovartis1969-12-31Not applicableCanada
Odan-tropicamideSolution1 %OphthalmicOdan Laboratories Ltd1985-12-31Not applicableCanada
Odan-tropicamideSolution0.5 %OphthalmicOdan Laboratories Ltd1985-12-31Not applicableCanada
PMS-tropicamide Oph Sltn 1%Solution / drops1 %OphthalmicPharmascience Inc1992-12-311996-09-09Canada
R.O.-tropamideLiquid10 mgOphthalmicRichmond Pharmaceuticals1992-12-311997-08-11Canada
TropicamideSolution1 %OphthalmicEberth Pharmaceuticals Inc1994-12-31Not applicableCanada
TropicamideSolution0.5 %OphthalmicEberth Pharmaceuticals Inc1994-12-31Not applicableCanada
Tropicamide 1% - Liq Oph 10mg/mlLiquid10 mgOphthalmicRivex Ophthalmics Inc.1997-09-152003-07-28Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MydriacylSolution / drops10 mg/mLOphthalmicAlcon, Inc.1959-04-01Not applicableUs
MydriacylSolution / drops10 mg/mLOphthalmicAlcon, Inc.1959-04-01Not applicableUs
TropicamideSolution / drops5 mg/mLOphthalmicSandoz2000-06-09Not applicableUs
TropicamideSolution / drops5 mg/mLOphthalmicBauch & Lomb Incorporated1994-07-27Not applicableUs
TropicamideSolution / drops10 mg/mLOphthalmicSandoz2000-06-13Not applicableUs
TropicamideSolution / drops5 mg/mLOphthalmicAkorn2000-09-29Not applicableUs
TropicamideSolution / drops10 mg/mLOphthalmicNucare Pharmaceuticals, Inc.1994-07-27Not applicableUs
TropicamideSolution / drops10 mg/mLOphthalmicHenry Schein2015-05-13Not applicableUs
TropicamideSolution / drops10 mg/mLOphthalmicAkorn2000-09-29Not applicableUs
TropicamideSolution / drops10 mg/mLOphthalmicBauch & Lomb Incorporated1994-07-27Not applicableUs
International/Other Brands
Better (Taiwan Biotech) / Camide (Ibn Sina) / Ciclomidrin (Latinofarma) / Dilate (Incepta) / Eyetrop (Apex) / Losemin (Oasis) / Midax (Rompharm) / Midric (Sanbe) / Minims Tropicamide (Bausch & Lomb) / Mydral (Ocusoft) / Mydramide (Fischer) / Mydriacyl / Mydriaticum (Ciba Vision) / Mydricol (Unimed) / Ocu-Tropic (Ocumed) / Tropicacyl (Akorn)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Diophenyl-T SolutionTropicamide (0.8 %) + Phenylephrine hydrochloride (5 %)SolutionOphthalmicSandoz Canada Incorporated1994-12-31Not applicableCanada
ParemydTropicamide (2.5 mg/mL) + Hydroxyamfetamine hydrobromide (10 mg/mL)SolutionOphthalmicAkorn1992-01-30Not applicableUs
Phenyltrope Oph SolnTropicamide (0.8 %) + Phenylephrine hydrochloride (5.0 %)SolutionOphthalmicSandoz Canada Incorporated1985-12-31Not applicableCanada
Categories
UNII
N0A3Z5XTC6
CAS number
1508-75-4
Weight
Average: 284.3529
Monoisotopic: 284.152477894
Chemical Formula
C17H20N2O2
InChI Key
BGDKAVGWHJFAGW-UHFFFAOYSA-N
InChI
InChI=1S/C17H20N2O2/c1-2-19(12-14-8-10-18-11-9-14)17(21)16(13-20)15-6-4-3-5-7-15/h3-11,16,20H,2,12-13H2,1H3
IUPAC Name
N-ethyl-3-hydroxy-2-phenyl-N-(pyridin-4-ylmethyl)propanamide
SMILES
CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1

Pharmacology

Indication

Indicated to induce mydriasis (dilation of the pupil) and cycloplegia (paralysis of the ciliary muscle of the eye) in diagnostic procedures, such as measurement of refractive errors and examination of the fundus of the eye.

Structured Indications
Not Available
Pharmacodynamics

Tropicamide belongs to the group of medicines called anti-muscarinics. Tropicamide blocks the receptors in the muscles of the eye (muscarinic receptors). These receptors are involved controlling the pupil size and the shape of the lens. By blocking these receptors, tropicamide produces dilatation of the pupil (mydriasis) and prevents the eye from accommodating for near vision (cycloplegia). Tropicamide is given as eye drops to dilate the pupil and relax the lens so that eye examinations can be carried out thoroughly.

Mechanism of action

Tropicamide binds to and blocks the receptors in the muscles of the eye (muscarinic receptor M4). Tropicamide acts by blocking the responses of the iris sphincter muscle to the iris and ciliary muscles to cholinergic stimulation, producing dilation of the pupil and paralysis of the ciliary muscle.

TargetActionsOrganism
AMuscarinic acetylcholine receptor M4
antagonist
Human
UMuscarinic acetylcholine receptor M1
antagonist
Human
UMuscarinic acetylcholine receptor M2
antagonist
Human
UMuscarinic acetylcholine receptor M3
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

45%

Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Overdose can casue dry mouth, blurred vision, photophobia, hallucinations and rapid/irregular pulse.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Tropicamide can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AclidiniumAclidinium may increase the anticholinergic activities of Tropicamide.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Tropicamide is combined with Alcuronium.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Tropicamide is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Tropicamide is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Ambenonium.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Anisotropine Methylbromide.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Tropicamide is combined with Atracurium.Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Tropicamide is combined with Atracurium besylate.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Tropicamide.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Tropicamide.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Tropicamide.Approved
BezitramideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Tropicamide is combined with Biperiden.Approved, Investigational
BornaprineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Bornaprine.Experimental
Botulinum Toxin Type ATropicamide may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BTropicamide may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Tropicamide is combined with Butorphanol.Approved, Illicit, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Tropicamide is combined with Carfentanil.Illicit, Investigational, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Tropicamide.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Chlorphenoxamine.Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Tropicamide.Approved
CimetropiumTropicamide may increase the anticholinergic activities of Cimetropium.Experimental, Investigational
CodeineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Codeine.Approved, Illicit
CoumaphosThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Coumaphos.Vet Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Tropicamide.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Tropicamide is combined with Cyclopentolate.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Tropicamide is combined with Darifenacin.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Demecarium.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Desloratadine.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Dexetimide.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Tropicamide is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Dezocine.Approved, Investigational
DichlorvosThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Dicyclomine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Dihydromorphine.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Tropicamide is combined with Diphenoxylate.Approved, Illicit
DistigmineThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Donepezil.Approved
DPDPEThe risk or severity of adverse effects can be increased when Tropicamide is combined with DPDPE.Investigational
DronabinolTropicamide may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Edrophonium.Approved
EluxadolineTropicamide may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Tropicamide is combined with Emepronium.Experimental
EtanautineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Tropicamide.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Etybenzatropine.Experimental
FentanylThe risk or severity of adverse effects can be increased when Tropicamide is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Fesoterodine.Approved
GalantamineThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Gallamine Triethiodide.Approved
Glucagon recombinantThe risk or severity of adverse effects can be increased when Tropicamide is combined with Glucagon recombinant.Approved
GlycopyrroniumTropicamide may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Tropicamide is combined with Heroin.Approved, Illicit, Investigational
HexamethoniumThe risk or severity of adverse effects can be increased when Tropicamide is combined with Hexamethonium.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Tropicamide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Tropicamide is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Tropicamide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Tropicamide is combined with Hydromorphone.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Hyoscyamine.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Tropicamide.Approved
IpidacrineThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Ipidacrine.Experimental
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tropicamide.Approved
IsoflurophateThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Tropicamide.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Tropicamide is combined with Ketobemidone.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Tropicamide is combined with Levomethadyl Acetate.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Tropicamide is combined with Levorphanol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Tropicamide is combined with Lofentanil.Illicit
MalathionThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Malathion.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Tropicamide is combined with Mazaticol.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Mecamylamine.Approved
MefloquineThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Memantine.Approved, Investigational
MeptazinolThe risk or severity of adverse effects can be increased when Tropicamide is combined with Meptazinol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Tropicamide is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Tropicamide is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Methantheline.Approved, Investigational
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Tropicamide.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Methylscopolamine bromide.Approved
MetixeneThe risk or severity of adverse effects can be increased when Tropicamide is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Tropicamide.Approved
MianserinMianserin may increase the anticholinergic activities of Tropicamide.Approved, Investigational
MinaprineThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Tropicamide is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Morphine.Approved, Investigational
NabiloneTropicamide may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Nalbuphine.Approved
NeostigmineThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NicomorphineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Nicomorphine.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Tropicamide is combined with Normethadone.Approved, Illicit
OpiumThe risk or severity of adverse effects can be increased when Tropicamide is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Orphenadrine.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Tropicamide is combined with Otilonium.Experimental, Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Tropicamide is combined with Oxitropium.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Tropicamide is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Tropicamide is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Tropicamide is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Tropicamide is combined with Oxyphenonium.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Tropicamide is combined with Pancuronium.Approved
ParaoxonThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Paraoxon.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Tropicamide is combined with Pentolinium.Approved
PethidineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Phenglutarimide.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Phenoperidine.Experimental
PhysostigmineThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Physostigmine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Tropicamide is combined with Pipecuronium.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Pirenzepine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Piritramide.Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Tropicamide.Approved
Potassium ChlorideTropicamide may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Tropicamide.Approved, Investigational
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Tropicamide.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Propantheline.Approved
PropiverineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Propiverine.Approved, Investigational
PyridostigmineThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Tropicamide.Approved
QuinidineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Quinidine.Approved
RamosetronTropicamide may increase the constipating activities of Ramosetron.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Tropicamide is combined with Remifentanil.Approved
RivastigmineThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Rivastigmine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tropicamide.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Scopolamine butylbromide.Approved, Vet Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Tropicamide.Approved, Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Tropicamide is combined with Solifenacin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Tropicamide is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Tropicamide.Approved, Investigational
TacrineThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Tropicamide is combined with Tapentadol.Approved
TilidineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Tilidine.Experimental
TiotropiumTropicamide may increase the anticholinergic activities of Tiotropium.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Tropicamide is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tropicamide is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Tropicamide.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Tropicamide.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Tropicamide is combined with Trimethaphan.Approved, Investigational
TropatepineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Tropatepine.Experimental
TrospiumThe risk or severity of adverse effects can be increased when Tropicamide is combined with Trospium.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tropicamide is combined with Tubocurarine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Tropicamide.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Tropicamide is combined with Vecuronium.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB14947
KEGG Drug
D00397
PubChem Compound
5593
PubChem Substance
46505924
ChemSpider
5391
BindingDB
82371
ChEBI
9757
ChEMBL
CHEMBL1200604
Therapeutic Targets Database
DAP000345
PharmGKB
PA164749389
Drugs.com
Drugs.com Drug Page
Wikipedia
Tropicamide
ATC Codes
S01FA06 — TropicamideS01FA56 — Tropicamide, combinations
AHFS Codes
  • 52:24.00 — Mydriatics
MSDS
Download (73.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedPreventionIntraocular Pressure1
2CompletedTreatmentSialorrhea Secondary to Parkinson's Disease1
3CompletedTreatmentCataracts1
3CompletedTreatmentEye Diseases1
4Active Not RecruitingTreatmentCorneal Transplant / Grafting, Corneal / Keratoplasty, Lamellar / Transplantation, Cornea / Transplantation, Corneal1
4CompletedDiagnosticPreterm Infants1
4Unknown StatusDiagnosticRefractive Errors1
4Unknown StatusPreventionMyopia1
Not AvailableCompletedNot AvailableFabry's Disease1
Not AvailableCompletedTreatmentCataracts1

Pharmacoeconomics

Manufacturers
  • Alcon laboratories inc
  • Pharmafair inc
  • Akorn inc
  • Alcon universal ltd
  • Bausch and lomb pharmaceuticals inc
  • Miza pharmaceuticals usa inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
SolutionOphthalmic
SolutionOphthalmic0.5 %
SolutionOphthalmic1 %
Solution / dropsOphthalmic1 %
LiquidOphthalmic10 mg
Solution / dropsOphthalmic10 mg/mL
Solution / dropsOphthalmic5 mg/mL
Prices
Unit descriptionCostUnit
Tropicamide powder72.83USD g
Mydriacyl 1% Solution 15ml Bottle59.84USD bottle
Tropicamide 0.5% Solution 15ml Bottle17.99USD bottle
Tropicamide 1% Solution 15ml Bottle17.75USD bottle
Mydriacyl 1% Solution 3ml Bottle17.28USD bottle
Tropicamide 1% Solution 3ml Bottle13.99USD bottle
Tropicamide 1% Solution 2ml Bottle7.99USD bottle
Mydriacyl 1% eye drops5.54USD ml
Tropicamide 1% eye drops2.52USD ml
Paremyd eye drops1.28USD ml
Mydriacyl 1 % Solution1.21USD ml
Tropicamide 0.5% eye drops1.06USD ml
Mydriacyl 0.5 % Solution0.94USD ml
Tropicacyl 1% eye drops0.71USD ml
Tropicacyl 0.5% eye drops0.67USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)96.5 °CPhysProp
logP1.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.375 mg/mLALOGPS
logP1.42ALOGPS
logP1.38ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)15.18ChemAxon
pKa (Strongest Basic)5.02ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area53.43 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity82.53 m3·mol-1ChemAxon
Polarizability29.78 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9943
Blood Brain Barrier+0.9777
Caco-2 permeable+0.5986
P-glycoprotein substrateNon-substrate0.5777
P-glycoprotein inhibitor INon-inhibitor0.8947
P-glycoprotein inhibitor IINon-inhibitor0.9442
Renal organic cation transporterNon-inhibitor0.6694
CYP450 2C9 substrateNon-substrate0.7731
CYP450 2D6 substrateNon-substrate0.7878
CYP450 3A4 substrateNon-substrate0.7241
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.895
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.8184
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6008
Ames testNon AMES toxic0.6905
CarcinogenicityNon-carcinogens0.7473
BiodegradationNot ready biodegradable0.8754
Rat acute toxicity2.4857 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9686
hERG inhibition (predictor II)Non-inhibitor0.8009
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.19 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0290000000-8c6533b9c36099d52c7c
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-1390000000-cf89fdf233a948aed049
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4r-4930000000-ca3db93b017c3a6fb89b

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylacetamides. These are amide derivatives of phenylacetic acids.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylacetamides
Direct Parent
Phenylacetamides
Alternative Parents
Pyridines and derivatives / Tertiary carboxylic acid amides / Heteroaromatic compounds / Azacyclic compounds / Primary alcohols / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Phenylacetamide / Pyridine / Tertiary carboxylic acid amide / Heteroaromatic compound / Carboxamide group / Azacycle / Organoheterocyclic compound / Carboxylic acid derivative / Hydrocarbon derivative / Organic oxygen compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Betz AJ, McLaughlin PJ, Burgos M, Weber SM, Salamone JD: The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors. Psychopharmacology (Berl). 2007 Oct;194(3):347-59. Epub 2007 Jun 27. [PubMed:17594079]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Betz AJ, McLaughlin PJ, Burgos M, Weber SM, Salamone JD: The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors. Psychopharmacology (Berl). 2007 Oct;194(3):347-59. Epub 2007 Jun 27. [PubMed:17594079]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Betz AJ, McLaughlin PJ, Burgos M, Weber SM, Salamone JD: The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors. Psychopharmacology (Berl). 2007 Oct;194(3):347-59. Epub 2007 Jun 27. [PubMed:17594079]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Betz AJ, McLaughlin PJ, Burgos M, Weber SM, Salamone JD: The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors. Psychopharmacology (Berl). 2007 Oct;194(3):347-59. Epub 2007 Jun 27. [PubMed:17594079]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34